Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/10/2024 | $80.00 | Buy | BofA Securities |
| 12/20/2023 | $43.00 | Buy | BTIG Research |
| 8/8/2023 | Outperform | TD Cowen | |
| 8/8/2023 | $40.00 | Outperform | Wedbush |
| 8/8/2023 | $29.00 | Buy | Guggenheim |
| 8/8/2023 | $34.00 | Buy | Stifel |
| 8/8/2023 | $29.00 | Buy | Jefferies |
SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it will host its virtual R&D Day at 10:00 a.m. ET on Monday, December 2, 2024. The event will include presentations from management discussing updates across Apogee's programs, highlighting APG777's best-in-class potential in AD, the significant role of
Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support potential best-in-class profile On track to report Phase 2 Part A data for APG777 in 2H 2025, interim Phase 1 data for APG808 in 4Q 2024 and interim Phase 1 data for APG990 in 1H 2025 APG333 development candidate selected and accelerating initiation of Phase 1 in late 2024 or early 2025; potential to offer best-in-class combination efficacy across multiple respiratory indications Plans advancing for combination studies, starting with the first clinical trial of the APG777 and APG990 combination for the treatment of AD in 2025 $754 million cash,
SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that members of management will participate at the following investor conferences. Guggenheim Inaugural Healthcare Innovation Conference Date: Tuesday, November 12, 2024Time: 3:00 p.m. ET Stifel 2024 Healthcare ConferenceDate: Monday, November 18, 2024Time:
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio? QuantumScape Corporation (NYSE:QS) stock jumped 64.34% after the company announced it entered into an agreement with Volkswagen's battery company PowerCo to industrialize solid-state batteries. Lantheus Holdings, Inc. (NASDAQ:LNTH) shares rocketed 55.93% following a CMS proposal to improve payment for Specialized Diagnostic Radiopharmaceuticals. Sunrun Inc. (NASDAQ:RUN) shares increased 37.59%. as shares of companies within the broader industrial sector gained following recent CPI data. Kymera Therapeutics, Inc. (NASDAQ:KYMR) shares rose 37.38% after the company announced its intentio
U.S. stocks were mostly higher, with the Dow Jones index gaining around 100 points on Thursday. Shares of Methode Electronics, Inc. (NYSE:MEI) rose sharply during Thursday's session after the company reported better-than-expected fourth-quarter sales results. Methode Electronics reported a fourth-quarter fiscal 2024 net sales decline of 7.9% year-on-year to $277.30 million, beating the analyst consensus estimate of $264.04 million. Adjusted EPS loss of 23 cents missed the analyst consensus loss estimate of 20 cents, according to data from Benzinga Pro. Methode Electronics shares surged 29.4% to $12.22 on Thursday. Here are some other big stocks recording gains in today’s session.
Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile 16-week proof-of-concept data from Part A of the Phase 2 trial expected in 2H 2025Pipeline-in-a-product potential with a Phase 2 in asthma expected to initiate in 2025 and plans for additional indication expansionSAN FRANCISCO and WALTHAM, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammat
BofA Securities initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $80.00
BTIG Research initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $43.00
TD Cowen initiated coverage of Apogee Therapeutics with a rating of Outperform
10-Q - Apogee Therapeutics, Inc. (0001974640) (Filer)
8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
144 - Apogee Therapeutics, Inc. (0001974640) (Subject)
SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
SC 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)
SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
Pharmacokinetic data support potential best-in-class profile with potential for improved clinical responses from greater exposures in induction than currently available biologic therapies and maintenance dosing of every 3- or 6-months Single dose showed deep and sustained inhibition of key atopic dermatitis biomarkers pSTAT6 and TARC for ~3 months (longest follow-up available with inhibition still ongoing at time of data cut) APG777 was well tolerated with a favorable safety profile consistent with the anti-IL-13 class Company plans to initiate a randomized, placebo-controlled, 16-week Phase 2 clinical trial in patients with moderate-to-severe atopic dermatitis in 1H 2024 with induction r
SAN FRANCISCO and WALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology (I&I) indications, today announced it will report interim results from the Phase 1 APG777 healthy volunteer trial on Tuesday, March 5, 2024. Following the announcement, the Company will host a conference call and webcast at 7:00am ET to discuss the results. To access the live and archived webcast, please visit the Investor Relations page of Apogee's website at https://investors.apogeeth
SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it will host its virtual R&D Day at 10:00 a.m. ET on Monday, December 2, 2024. The event will include presentations from management discussing updates across Apogee's programs, highlighting APG777's best-in-class potential in AD, the significant role of
SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other I&I indications, today announced the appointment of Jeff S. Hartness as Chief Commercial Officer. Mr. Hartness has an extensive track record in commercial and corporate leadership, bringing more than 25 years of experience in the biotech industry focused on product launches, market access strategy,
SAN FRANCISCO and WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Lisa Bollinger, MD, has been appointed to the company's board of directors. Dr. Bollinger most recently served as Vice President, Regulatory Affairs, Global Regulatory Affairs and Clinical Safety (GRACS) at Merck, where she led the general medicine therapeutic area in regulatory affairs. Dr. Bollinger's over 30 years of experience in drug development,